|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Cohort** | **ATE (95% CI)** | | | **n** |
| **Treatment** | **None** | **IMV** | **VP** |  |
| No cancer | 30% (30 - 31%) | 1% (0 - 1%) | 0% (-1 - 0%) | 19,744 |
| Cancer | 62% (61 - 64%) | -2% (-4 - 0%) | -1% (-3 - 1%) | 3,875 |
| Solid | 48% (45 - 51%) | 0% (-4 - 3%) | 2% (-2 - 5%) | 1,430 |
| Hematological | 58% (55 - 62%) | -1% (-5 - 2%) | -7% (-11 - -4%) | 910 |
| Metastasized | 77% (75 - 80%) | -2% (-4 - 1%) | -1% (-3 - 2%) | 1,535 |